LogoCrystal's Coder Hub

C32.0

21 min read

🧬 ICD-10 CM C32.0 — Malignant Neoplasm of Glottis

Billable Code Confirmed

ICD-10 CM C32.0 is a valid, billable 5-character ICD-10-CM code effective for FY2026. It classifies malignant neoplasms arising at the glottis — the portion of the larynx comprising the true vocal cords and the laryngeal commissures — under Chapter 2 (Neoplasms), within the C30-C39 respiratory malignancy block. The 5-character specificity distinguishes glottic cancer from supraglottic (C32.1), subglottic (C32.2), and unspecified laryngeal cancers (C32.9). No additional characters are required; C32.0 is the terminal billable code at this level of the hierarchy.

Non-Billable Parent Codes

  • C32 (Malignant neoplasm of larynx) — Non-billable header category; captures all laryngeal sites collectively but lacks the subsite specificity required for submission. A fourth character identifying the laryngeal subsite (glottis, supraglottis, subglottis, etc.) is always required.
  • C30-C39 block header — Non-billable; this is a range descriptor for respiratory and intrathoracic malignancies in the Tabular, not an assignable code.

Clinical Context

Glottic cancer arises from the true vocal cords and is the most common laryngeal cancer subtype, accounting for approximately 60-65% of all laryngeal malignancies. The glottis includes the true vocal cords, the anterior commissure, and the posterior commissure — all captured under C32.0. Its anatomical location gives it an early clinical signature (hoarseness) that often leads to earlier detection compared to supraglottic or subglottic tumors. This distinction in subsite is clinically and prognostically significant: glottic tumors have a lower rate of lymphatic spread due to the relatively sparse lymphatic supply of the true vocal cords, giving them a generally more favorable prognosis than supraglottic cancers.

Code Classification

ICD-10 CM C32.0 is a malignant neoplasm (diagnosis) code — it represents an active, primary invasive cancer of the glottic larynx. It is not a carcinoma-in-situ code (that would be D02.0), not a history-of-cancer code (Z85.118), and not a secondary/metastatic code. It is not an ICD-10-PCS procedure code or a CPT code.

🔍 Code Description

ICD-10 CM C32.0 classifies primary malignant neoplasm arising from the glottis, which is the middle segment of the larynx housing the true vocal cords. According to ICD-10-CM inclusion terms, C32.0 encompasses malignant neoplasms of the intrinsic larynx, the anterior laryngeal commissure, the posterior laryngeal commissure, and the true vocal cord itself. The vast majority of glottic cancers are squamous cell carcinoma (SCC) histologically, arising from the stratified squamous epithelium lining the vocal cords, with tobacco use and alcohol consumption identified as the dominant risk factors. The glottis is anatomically distinct from the supraglottis (epiglottis, aryepiglottic folds, arytenoids, false vocal cords) coded at C32.1 and from the subglottis coded at C32.2.

In the inpatient setting, C32.0 drives MS-DRG assignment to MDC 3 (Ear, Nose, Mouth and Throat Diseases) in the medical DRG tier, but the encounter frequently involves significant surgical procedures — particularly total laryngectomy, partial laryngectomy, or tracheostomy — that shift the grouping to the higher-weighted surgical DRGs 011-013. Glottic cancers are staged using the AJCC/TNM system, and the extent of disease at admission (early glottic T1-T2 vs. advanced T3-T4 with cord fixation or extralaryngeal spread) significantly affects LOS, treatment complexity, and DRG weight. Coders should capture all secondary diagnoses — including metastatic disease, tracheostomy status, dysphagia, and malnutrition — to ensure accurate CC/MCC assignment and complete clinical picture representation.

🌳 Code Tree / Hierarchy

C32  Malignant neoplasm of larynx ❌ Non-billable
│
├── C32.0  Malignant neoplasm of glottis ◀ THIS CODE ✅ Billable
│           (Includes: intrinsic larynx, true vocal cord,
│            anterior commissure, posterior commissure)
│
├── C32.1  Malignant neoplasm of supraglottis ✅ Billable
│           (Includes: aryepiglottic fold, epiglottis,
│            false vocal cord, posterior surface of epiglottis)
│
├── C32.2  Malignant neoplasm of subglottis ✅ Billable
│
├── C32.3  Malignant neoplasm of laryngeal cartilage ✅ Billable
│
├── C32.8  Malignant neoplasm of overlapping sites of larynx ✅ Billable
│
└── C32.9  Malignant neoplasm of larynx, unspecified ✅ Billable

Glottis vs. Supraglottis: Subsite Specificity Is Non-Negotiable

Assigning C32.0 (glottis) vs. C32.1 (supraglottis) is not a minor distinction — these subsites have different lymphatic drainage patterns, TNM staging criteria, treatment approaches, and survival outcomes. If provider documentation specifies “laryngeal cancer” without identifying the subsite, query for clarification before defaulting to C32.9 (unspecified). Payer auditors and registry requirements both demand subsite-specific coding, and C32.9 may trigger documentation queries under value-based care programs.

Overlapping Laryngeal Sites

When a laryngeal tumor spans more than one subsite (e.g., extending from the glottis into the supraglottis), and the point of origin cannot be determined, assign C32.8 (Malignant neoplasm of overlapping sites of larynx) rather than coding both C32.0 and C32.1. Only assign multiple laryngeal subsite codes if they are clearly identified as separate primary tumors by the provider.

✅ Includes

  • Malignant neoplasm of intrinsic larynx: The intrinsic larynx refers to the internal portion containing the true vocal cords; this inclusion term confirms C32.0 covers cancers described as “intrinsic laryngeal” in provider documentation.
  • Malignant neoplasm of true vocal cord: Squamous cell carcinomas of the true vocal cord are the most common presentation of glottic cancer; documentation stating “true vocal cord carcinoma” maps directly to C32.0.
  • Malignant neoplasm of anterior laryngeal commissure: The anterior commissure is where the two true vocal cords meet anteriorly at the thyroid cartilage; tumors here are aggressive with higher rates of thyroid cartilage invasion.
  • Malignant neoplasm of posterior laryngeal commissure: The posterior commissure connects the vocal cords posteriorly between the arytenoid cartilages; involvement here can impair cord mobility and alter staging.
  • Glottic squamous cell carcinoma: The overwhelming histological majority of C32.0 cases are SCC; other rare histologies (verrucous carcinoma, neuroendocrine carcinoma) arising at this site are also captured here.

❌ Excludes

Excludes 1

These codes represent mutually exclusive conditions — do not assign with C32.0:

  • D02.0 — Carcinoma in situ of larynx: This code represents a pre-invasive (in situ) laryngeal malignancy where the abnormal cells have not penetrated the basement membrane. C32.0 represents invasive malignancy; by ICD-10-CM classification rules, in situ and invasive malignancy of the same site cannot be coded simultaneously. If biopsy confirms transition from in situ to invasive, assign C32.0 only when the provider documents invasive cancer.

In Situ vs. Invasive — Critical Audit Point

Assigning both D02.0 and C32.0 for the same laryngeal site is a hard Excludes 1 violation and will fail claim edits. This is particularly relevant in ENT and oncology encounters where biopsy results may describe “carcinoma in situ with focal invasive component” — in these cases, query the provider to confirm whether the final diagnosis is in situ or invasive before code assignment. Coding from pathology reports without provider confirmation of the clinical diagnosis is non-compliant.

Excludes 2

These conditions are not included in C32.0 but may be coded additionally when clinically documented:

  • C77.0 — Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck: Regional lymph node metastasis from glottic cancer, when documented, should be coded separately with C77.0. Glottic cancers have lower rates of nodal spread than supraglottic tumors due to sparse vocal cord lymphatics, but advanced-stage disease or transglottic extension increases nodal risk.
  • C78.39 — Secondary malignant neoplasm of other and unspecified respiratory organs: Distant metastasis to the lung or other respiratory sites from a glottic primary should be coded with the appropriate secondary neoplasm code alongside C32.0. When metastatic disease is the reason for admission, the metastatic site code may be sequenced as the principal diagnosis depending on clinical circumstances.

📋 Clinical Overview

Glottic vs. Other Laryngeal Subsite Cancers

Accurate subsite coding directly impacts staging, treatment planning, and reimbursement. Glottic cancers (C32.0) present earlier due to voice changes and generally carry a better prognosis than supraglottic cancers because the true vocal cords have minimal lymphatic drainage, reducing early nodal spread. In contrast, supraglottic cancers (C32.1) often remain occult longer and present with more advanced nodal disease. Subglottic cancers (C32.2) are the rarest subtype and have the worst prognosis due to circumferential tracheal involvement risk.

FeatureC32.0 GlottisC32.1 SupraglottisC32.2 Subglottis
Primary structuresTrue vocal cords, anterior/posterior commissures, intrinsic larynxEpiglottis, aryepiglottic folds, false vocal cords, arytenoidsSubglottic space below true cords to inferior cricoid border
Early symptomHoarseness (early and prominent)Dysphagia, throat pain, referred otalgia (late hoarseness)Stridor, airway compromise (symptoms appear late)
Lymphatic drainageSparse — lower rate of early nodal spreadRich — high rate of bilateral nodal involvementRich — paratracheal and mediastinal nodes at risk
Relative frequency~60-65% of laryngeal cancers~30-35% of laryngeal cancers~1-5% of laryngeal cancers
Prognosis (early stage)Favorable — 5-year OS ~83.6% for early glotticWorse — 5-year OS ~64.9% for early supraglotticPoor — often advanced at diagnosis
DRG (medical, no O.R.)DRG 146/147/148DRG 146/147/148DRG 146/147/148

CDI Trigger — Subsite and Staging Documentation

One of the highest-yield CDI opportunities for laryngeal cancer encounters is prompting providers to document not only the subsite (glottis, supraglottis, subglottis) but also the clinical or pathological stage (T, N, M), histology, and current treatment status. Incomplete documentation defaults to C32.9 (unspecified larynx), which fails to reflect true clinical complexity, may underperform for HCC capture under CMS-HCC V28 HCC 12, and reduces registry data quality.

Manifestations & Symptom Burden

  • Hoarseness/Dysphonia: The hallmark early symptom of glottic cancer; caused by tumor mass altering true vocal cord vibration — a CDI documentation opportunity if the provider lists “voice change” without specifying the neoplasm as the cause.
  • Dysphagia: May occur with advanced glottic tumors extending to the supraglottis or hypopharynx; code additionally with R13.10-R13.19 when documented.
  • Stridor/Airway Obstruction: Advanced or T3-T4 glottic tumors with fixed vocal cord or transglottic extension may cause stridor and require emergent airway management; a tracheostomy during the encounter shifts the MS-DRG significantly.
  • Aspiration/Aspiration Pneumonia: Post-treatment (post-laryngectomy or post-radiation) aspiration is a common comorbidity; when documented, J69.0 should be captured as an additional code.
  • malnutrition: Head and neck cancer treatment frequently leads to protein-calorie malnutrition; E43 or E44.x, when documented, may qualify as a CC or MCC and directly impacts DRG weight — a top CDI capture opportunity in this population.

Manifestation and Comorbidity Coding

ICD-10 CM C32.0 is a principal diagnosis code — it does not follow another code. However, secondary conditions like metastatic disease, malnutrition, aspiration pneumonia, tracheostomy status (Z93.0), and post-laryngectomy voice rehabilitation are all separately codeable comorbidities that enrich the clinical picture, support medical necessity, and directly affect DRG weight and reimbursement. Missing these secondary codes is a common inpatient coding gap in oncology encounters.

💰 HCC Risk Adjustment

HCC ModelHCC CategoryRelative RAF WeightNotes
CMS-HCC V28 (2026)HCC 12 — Lung and Other Severe CancersHigh (significant RAF contribution)Fully implemented PY2026; direct ICD-10 to HCC mapping
CMS-HCC V24 (legacy, phased out 2026)HCC 12 — Lung and Other Severe CancersHighV24 fully replaced by V28 for PY2026
CDPS / MedicaidCancer — High-Cost Neoplasm tierVaries by state modelCaptured as high-complexity active malignancy

C32.0 maps to HCC 12 (Lung and Other Severe Cancers) under CMS-HCC V28, which is the fully operational model for payment year 2026 following its three-year phase-in from 2024-2026. HCC 12 carries a substantial RAF weight, reflecting the significant predicted cost burden of active severe malignancies, including laryngeal cancer requiring surgery, radiation, and/or chemotherapy. This code must represent an active, current malignancy — not a resolved cancer or personal history — to support HCC 12 capture. Annual documentation refresh is essential in Medicare Advantage and ACO REACH contracts: if providers do not document ongoing active cancer management each calendar year, the HCC cannot be recaptured and the patient’s risk score will drop. CDI and coding teams should work with oncology providers to ensure C32.0 is documented and coded during all eligible encounters where the patient is actively receiving treatment or being monitored for active disease.

🏥 MS-DRG Assignment

ICD-10 CM C32.0 drives MS-DRG assignment to MDC 3 — Ear, Nose, Mouth and Throat Diseases when it is the principal diagnosis. DRG assignment then depends on whether a qualifying O.R. procedure is performed and the CC/MCC burden.

Clinical ScenarioPrincipal DxO.R. Procedure?MS-DRGNotes
Medical management, chemo, or radiation onlyC32.0NoDRG 146 (w/MCC), 147 (w/CC), 148 (w/o CC/MCC)Standard medical ENT malignancy DRGs
Total laryngectomy performedC32.0Yes (laryngectomy)DRG 011 (w/MCC), 012 (w/CC), 013 (w/o CC/MCC)Laryngectomy = tracheostomy for face/mouth/neck Dx; dramatically higher relative weight
Tracheostomy performed (without laryngectomy)C32.0Yes (tracheostomy)DRG 011, 012, or 013Tracheostomy also triggers the surgical DRG shift
C32.0 as secondary dx, respiratory failure as principalJ96.xxNoRespiratory failure DRGC32.0 may function as CC; assess exclusion list

When C32.0 is the principal diagnosis and no qualifying O.R. procedure is performed, CC/MCC burden from secondary diagnoses (malnutrition, aspiration pneumonia, metastatic disease, respiratory failure, dysphagia) determines whether the case lands in DRG 146 vs. 147 vs. 148, with DRG 146 (MCC present) yielding the highest weight. Coders must confirm the presence of all documented comorbidities that meet CC/MCC criteria, as head and neck cancer patients frequently carry multiple high-complexity comorbidities. When a laryngectomy or tracheostomy is performed, the DRG 011-013 grouping carries a substantially higher relative weight than the medical DRGs — making accurate O.R. procedure coding in ICD-10-PCS a critical reimbursement driver in these encounters.

🔗 Related ICD-10-CM Codes

Laryngeal Malignancy Subsites:

  • C32.1 — Malignant neoplasm of supraglottis (epiglottis, aryepiglottic folds, false cords)
  • C32.2 — Malignant neoplasm of subglottis
  • C32.3 — Malignant neoplasm of laryngeal cartilage
  • C32.8 — Malignant neoplasm of overlapping sites of larynx
  • C32.9 — Malignant neoplasm of larynx, unspecified (avoid — query for subsite)

Related Staging, History, and Status Codes:

  • D02.0 — Carcinoma in situ of larynx (pre-invasive; Excludes 1 with C32.0 at same site)
  • Z85.118 — Personal history of malignant neoplasm of other part of bronchus and lung (Note: use Z85.21 — Personal history of malignant neoplasm of larynx — for resolved glottic cancer)
  • Z85.21 — Personal history of malignant neoplasm of larynx
  • C77.0 — Secondary malignant neoplasm of lymph nodes of head, face and neck (regional mets)
  • C78.39 — Secondary malignant neoplasm of other and unspecified respiratory organs (distant mets)
  • Z93.0 — Tracheostomy status (post-laryngectomy or tracheostomy-dependent patients)

🛠️ Commonly Associated CPT Codes

  • 31365 — Laryngectomy; total, with radical neck dissection: Total laryngectomy with neck dissection is the definitive surgical treatment for advanced glottic cancer (T3-T4 or recurrent disease). This CPT is among the highest-acuity ENT procedures; on the inpatient facility side, the corresponding ICD-10-PCS laryngectomy code drives the DRG shift to 011/012/013. Documentation of neck dissection extent (selective vs. radical) is important for both CPT and PCS code selection.

  • 31360 — Laryngectomy; total, without radical neck dissection: Used for total laryngectomy when neck dissection is not performed. Like 31365, this procedure on the inpatient side triggers the surgical DRG grouping; coders must capture the PCS equivalent (excision/resection of larynx) for inpatient facility billing.

  • 31400 — Arytenoidectomy or arytenoidopexy, external approach: Performed in select glottic cancer cases or post-treatment cord fixation. This is a less commonly billed code but may appear in cases of bilateral cord paralysis following radiation or surgical treatment.

  • 77301 / 77385 / 77386 — Radiation therapy (IMRT planning/delivery): Intensity-modulated radiation therapy (IMRT) is a primary treatment for early-stage (T1-T2) glottic cancers as a voice-sparing alternative to surgery. These codes are predominantly outpatient/professional fee; inpatient radiation planning encounters would pair the radiation CPT with C32.0 as the supporting diagnosis. IMRT planning (77301) and delivery (77385/77386) may appear on the same claim or split across encounters.

  • 96413 / 96415 — Chemotherapy administration, intravenous infusion: When glottic cancer is managed with concurrent chemoradiation (cisplatin-based regimens are standard), chemotherapy infusion codes are billed on the professional side. Inpatient facility coding would capture the ICD-10-PCS equivalent for chemotherapy administration. Z51.11 (encounter for antineoplastic chemotherapy) should be coded when chemo is the reason for admission alongside C32.0.

  • 31600 — Tracheostomy, planned (separate procedure): Tracheostomy is frequently required for airway management in advanced glottic cancer patients pre- or post-laryngectomy, or during radiation. On the inpatient side, the ICD-10-PCS tracheostomy code is the O.R. procedure that triggers the DRG 011/012/013 grouping — making accurate PCS code capture a high-priority reimbursement issue for these encounters.

NCCI Bundling Considerations

For professional fee billing, NCCI edits commonly bundle diagnostic laryngoscopy (31575) into laryngeal surgical CPT codes (31360, 31365), so separate billing of the diagnostic laryngoscopy on the same date as a laryngectomy procedure will typically deny. Radiation therapy planning (77301) and initial delivery codes carry their own bundling edits with simulation and dosimetry codes — coders should verify which planning components are separately billable per payer policy. Chemotherapy administration codes (96413, 96415) bundle with injection/infusion codes performed on the same date, and only the highest-level service should be reported as the primary administration code with additional hours billed as add-on codes.

🔬 ICD-10-PCS Crosswalk

C32.0 is an ICD-10 CM diagnosis code. The following ICD-10-PCS codes are commonly assigned in inpatient encounters where C32.0 is the principal or secondary diagnosis:

  • 0CT30ZZ — Resection of Larynx, Open Approach: The PCS code for total laryngectomy performed via open approach. This is the O.R. procedure that shifts MS-DRG grouping from medical DRG 146/147/148 to the significantly higher-weighted surgical DRG 011/012/013. Accurate Root Operation selection (Resection for total removal vs. Excision for partial) is critical — use Resection only when the entire larynx is removed.

  • 0CB30ZZ — Excision of Larynx, Open Approach: Represents partial laryngectomy (hemilaryngectomy, cordectomy) when only a portion of the larynx is removed. Distinguishing Resection (total) from Excision (partial) in PCS is a top coder accuracy requirement in laryngeal cancer cases.

  • 0B110F4 — Bypass Trachea to Cutaneous, Tracheostomy Device, Open Approach: The ICD-10-PCS code for tracheostomy. Even without a laryngectomy, if a tracheostomy is performed during the inpatient stay for airway management in a glottic cancer patient, this PCS code is the O.R. procedure that can trigger the DRG 011/012/013 grouping, depending on MS-DRG logic.

  • 3E0G76Z — Introduction of Therapeutic Substance into Upper GI (chemotherapy): May be assigned for intraluminal chemotherapy administration in rare scenarios. More commonly, IV chemotherapy for head and neck cancer is captured via the circulatory system PCS administration codes (3E04305 for central venous).

💊 Coding Scenarios and Examples

Scenario 1 — Early-Stage Glottic SCC, Radiation Admission

A 62-year-old male with a 40-pack-year smoking history was admitted for initial management and radiation planning after biopsy-confirmed T1a squamous cell carcinoma of the left true vocal cord. The attending otolaryngologist documented “glottic carcinoma, true vocal cord, left, T1a, planned for definitive radiation therapy.” No surgical procedure was performed during this admission.

Correct Coding:

  • Principal Dx: C32.0 — Malignant neoplasm of glottis
  • Additional: F17.210 — Nicotine dependence, cigarettes, uncomplicated (if current smoker)

Sequencing: C32.0 is the condition chiefly responsible for admission (definitive cancer workup and radiation planning). No qualifying O.R. procedure performed, so MS-DRG 146/147/148 applies.
CDI Note: Confirm the provider documents “glottis” or “true vocal cord” — do not assign C32.0 from a pathology report alone stating “laryngeal SCC” without provider clarification of subsite. This is an HCC 12 capture opportunity that must be clearly documented in the provider’s clinical note.

Scenario 2 — Advanced Glottic Cancer, Total Laryngectomy

A 71-year-old female was admitted for total laryngectomy with selective neck dissection (levels II-IV) for T3N1M0 squamous cell carcinoma of the glottis with left cord fixation. She had a tracheostomy placed intraoperatively. Post-operative course was complicated by aspiration pneumonia on day 3, requiring IV antibiotics.

Correct Coding:

  • Principal Dx: C32.0 — Malignant neoplasm of glottis
  • Additional: C77.0 — Secondary malignant neoplasm of lymph nodes of head, face and neck (N1 disease)
  • Additional: J69.0 — Pneumonitis due to inhalation of food and vomit (aspiration pneumonia — MCC)
  • Additional: Z93.0 — Tracheostomy status
  • ICD-10-PCS: 0CT30ZZ — Resection of Larynx, Open Approach

Sequencing: C32.0 is principal; lymph node metastasis and aspiration pneumonia are secondary. The laryngectomy/tracheostomy procedure shifts grouping to DRG 011 (with MCC — aspiration pneumonia J69.0 is an MCC).
CDI Note: Aspiration pneumonia is the MCC here — confirm it is explicitly documented by the provider, not inferred from nursing notes. Query if documentation says “possible aspiration” or “aspiration risk” without confirming the diagnosis of aspiration pneumonia.

Scenario 3 — Recurrent Glottic Cancer, Chemotherapy Admission

A 68-year-old male with previously treated glottic SCC (prior radiation) was admitted for recurrent disease confirmed on biopsy and PET-CT, being admitted for initiation of cisplatin-based chemotherapy. The physician documented “recurrent malignant neoplasm of glottis, scheduled for chemotherapy.”

Correct Coding:

  • Principal Dx: Z51.11 — Encounter for antineoplastic chemotherapy
  • Additional: C32.0 — Malignant neoplasm of glottis (recurrent active disease)

Sequencing: Per ICD-10-CM guideline I.C.2.e, when the reason for admission is chemotherapy and the malignancy is also present, assign Z51.11 as principal and the malignancy code as secondary. C32.0 still captures for HCC 12 RAF credit as a secondary diagnosis.
CDI Note: Confirm “recurrent” is documented — if prior cancer was treated and there is now new disease, coding active C32.0 is appropriate. Do NOT code Z85.21 (personal history) when the cancer is active or recurrent; history codes are only for resolved cancers with no current treatment.

⚠️ Coding Pitfalls and Tips

  1. Assigning C32.9 (unspecified larynx) when the subsite is documented: The most common laryngeal cancer coding error is using C32.9 when provider documentation clearly states “glottic,” “true vocal cord,” “supraglottic,” or another specific subsite. C32.9 should only be used when the provider genuinely has not documented or cannot specify the laryngeal subsite. Using C32.9 when specificity is available loses the HCC 12 capture advantage (both map to HCC 12, but subsite specificity is required for cancer registry and quality reporting), fails to fully represent clinical complexity, and is a documentation quality flag under value-based programs.

  2. Coding D02.0 (in situ) alongside C32.0 (invasive): The Excludes 1 relationship between D02.0 and C32.0 means these codes can never be assigned together for the same laryngeal site. Coders who see “carcinoma in situ with invasive focus” in a pathology report must query the provider to confirm the final clinical diagnosis before assigning either code. The provider’s clinical documentation governs, not the pathology report language alone.

  3. Missing the DRG-shifting O.R. procedure: Total laryngectomy (ICD-10-PCS: 0CT30ZZ) and tracheostomy (0B110F4) shift the MS-DRG from the lower-weighted medical DRG 146/147/148 to the significantly higher-weighted surgical DRG 011/012/013. Failing to capture the corresponding ICD-10-PCS code for these procedures is a major reimbursement miss. Coders must review the operative report for every glottic cancer admission to confirm whether a qualifying O.R. procedure was performed.

  4. Using C32.0 when the cancer is resolved (should be Z85.21): C32.0 is an active malignancy code. When a patient has a history of glottic cancer that has been successfully treated with no evidence of active disease and no current treatment, assign Z85.21 (Personal history of malignant neoplasm of larynx) instead. Coding C32.0 for a history-only scenario overstates active disease, is non-compliant with ICD-10-CM guideline I.C.2, and constitutes a potential false claims risk in audited environments.

  5. Neglecting secondary diagnosis capture in head and neck cancer patients: Head and neck cancer patients are high-acuity with rich secondary diagnosis profiles — malnutrition (E43/E44.x), aspiration pneumonia (J69.0), dysphagia (R13.10-R13.19), tracheostomy status (Z93.0), and alcohol use disorder (F10.xx) are all common, frequently documented, and often CC- or MCC-level. Missing these codes reduces DRG weight, understates clinical complexity, and underperforms for risk adjustment. A thorough review of the H&P, nursing notes, and discharge summary is essential for every C32.0 inpatient encounter.

  6. Sequencing error when admission is for chemotherapy or radiation: Per ICD-10-CM guidelines I.C.2.e, when the sole purpose of admission is antineoplastic therapy (chemotherapy, immunotherapy, radiation), assign Z51.11 or Z51.12 as principal and C32.0 as an additional code — not the reverse. Incorrectly sequencing C32.0 as principal in a chemotherapy-only admission is a common compliance finding in oncology audits. However, if the patient is admitted for a complication of the malignancy (e.g., airway obstruction, hemorrhage) and receives chemo incidentally, C32.0 or the complication may be principal depending on UHDDS criteria.

📚 Sources

1 Centers for Disease Control and Prevention / NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2026, Section I.C.2 — Neoplasms. U.S. Department of Health and Human Services. 2025.
2 AAPC. ICD-10 Code C32.0 — Malignant neoplasm of glottis. AAPC Code Reference. 2023. https://www.aapc.com/codes/icd-10-codes/C32.0
3 icdlist.com. ICD-10-CM Diagnosis Code C32.0 — Malignant neoplasm of glottis. 2024. https://icdlist.com/icd-10/C32.0
4 VeroScribe / GenHealth AI. C32.0 ICD-10-CM — Malignant neoplasm of glottis. 2025. https://genhealth.ai/code/icd10cm/C32.0-malignant-neoplasm-of-glottis
5 Cancer Registry of Greater California. Larynx Coding Slides — Glottis (C32.0): Intrinsic Larynx, Laryngeal Commissure. 2017. https://crgc-cancer.org/wp-content/uploads/2013/10/Larynx-2017-Slides.pdf
6 National Cancer Institute SEER. ICD-10-CM to ICD-10 Crosswalk, FY2026. NCI SEER Cancer Statistics. 2025. https://seer.cancer.gov/tools/conversion/2026/ICD10CM-to-ICD10.FY2026.pdf
7 CMS. ICD-10-CM/PCS MS-DRG v37.0 Definitions Manual — MDC 3, DRG 011-013, 146-148. Centers for Medicare & Medicaid Services. https://www.cms.gov/icd10m/version37-fullcode-cms/fullcode_cms/P0046.html
8 CMS. 2026 Model Software/ICD-10 Mappings — CMS-HCC V28. Centers for Medicare & Medicaid Services, Risk Adjustment. 2025. https://www.cms.gov/medicare/payment/medicare-advantage-rates-statistics/risk-adjustment/2026-model-software-icd-10-mappings
9 Pinheiro LC, et al. Outcome Disparities in Patients with Early-Stage Laryngeal Squamous Cell Carcinoma — Glottic vs. Supraglottic. PMC/NIH. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11428932/
10 ParaDocs Health. Understanding CMS HCC v28 in 5 Minutes. 2025. https://www.paradocshealth.com/post/understanding-cms-hcc-v28-in-5-minutes

Graph View

Recent Notes